sellModerate cluster of 410b5-1 plan
Joseph P Hagan sold $160k of RGLS
Chief Executive Officer at Regulus Therapeutics Inc.. 127,054 shares at an average of $1.26, traded Jan 13, 2025, filed Jan 15, 2025.
Warning score
41Value
$160k
127,054 shares
Holdings after
210,808
-38% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +11Trade size$160k at market
- +10Share of holdings soldSold 38% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-005883, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 13, 2025 | SOpen-market sale Common Stock10b5-1 | -115,290 | $1.26 | $146k | 222,572 | Jan 15, 2025 |
| Jan 14, 2025 | SOpen-market sale Common Stock10b5-1 | -11,764 | $1.26 | $15k | 210,808 | Jan 15, 2025 |
Related signals
Other insiders at Regulus Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | RGLSbuy Regulus Therapeutics Inc. | Preston Klassen President & Head of R & D | $96k 12,000 shares | +33% | |
| 33Weak | Regulus Therapeutics Inc. | David Baltimore director | $21k 19,610 shares | +766% | |
| 46Moderate | Regulus Therapeutics Inc. | Joseph P Hagan Chief Executive Officer | $54k 50,000 shares | +24% | |
| 27Weak | Regulus Therapeutics Inc. | Christopher Ray Aker Sr. VP & General Counsel | $55k 43,635 shares | -47% | |
| 34Weak | Regulus Therapeutics Inc. | Crispina Calsada Chief Financial Officer | $55k 43,804 shares | -49% | |
| 31Weak | Regulus Therapeutics Inc. | Preston Klassen President & Head of R & D | $40k 31,445 shares | -47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.